Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold and lowers the price target from $3 to $2.
Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold and lowers the price target from $3 to $2.